MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Improving Treatment Of Anemia

Back to health Blogs list Cancer blog  


Subscribe To Health RSS Feed  RSS content feed What is RSS feed?

Improving Treatment Of Anemia




Researchers at the University of California, San Diego (UCSD) have determined a key mechanism by which the body regulates iron metabolism, a discovery that may provide new approaches for the therapy of anemia.

The findings, which are reported this week in the online publication of The Journal of Clinical Investigation, represent a collaborative effort between the laboratories of Randall Johnson, Ph.D., UCSD professor of biology and Victor Nizet, M.D., professor of pediatrics and pharmacy at the UCSD School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences.



Improving Treatment Of Anemia

Iron is essential for a number of normal biological processes including the production red blood cells that deliver oxygen to the body's tissues. By studying the regulation of iron and production of red blood cells in mice, the scientists established the relationship between a pair of proteins that play a central role in monitoring a hormone called hepcidin.

The hepcidin hormone is a peptide, or small protein, that is synthesized in the liver and regulates the levels of iron in the body. It prevents the body from absorbing more iron than is needed from food or supplements, and blocks the export of iron from cells.

Patients with cancer, chronic inflammatory diseases or infections often develop high levels of hepcidin, which reduces the amount of iron available to support the production of new red blood cells. Consequently, such patients suffer from low red blood cell production, or anemia.

To properly respond to anemia, the body must somehow reduce hepcidin in order to increase the iron that is needed for red blood cell production. Until now, researchers didn't clearly understand the mechanisms by which hepcidin itself is regulated.

The UCSD research team discovered that a protein known as hypoxia-inducible transcription factor (HIF) is critical in orchestrating the proper hepcidin response in the liver. In turn, HIF levels are controlled on a minute-by-minute basis by the action of another protein known as von-Hippel Lindau factor (vHL.).

The vHL factor works to lower HIF levels whenever oxygen is high or iron is abundant, said Johnson. When iron levels and oxygen delivery to the tissues drop, as is the case in anemia, vHL ceases its action and HIF is preserved.

Prior research had shown that HIF is responsible for stimulating erythropoietin (EPO), a hormone that instructs the bone marrow to produce new red blood cells. The UCSD team made the critical and novel observation that HIF also strongly inhibits the production of hepcidin in the liver.

Our findings show that the vHL and HIF proteins play a central role in sensing and regulating iron levels, said lead author Carole Peyssonnaux, Ph.D., a former researcher with Nizet and Johnson who has now joined the faculty of the Institut Cochin in Paris, France. In anemia, the body responds to low iron and oxygen levels by increasing HIF, which in turn suppresses hepcidin and boosts EPO to provide the iron and new red blood cells mandatory to correct the problem.

Importantly, the scientists observed that HIF was capable of suppressing hepcidin even in mice suffering inflammatory changes in their bodies.

This key finding suggests that new drug therapy strategies to boost HIF or inhibit vHL could reverse the abnormally high hepcidin levels seen in the anemia that affects the majority of patients suffering from chronic infections or inflammatory disease, said Nizet.


Posted by: Sue    Source




Did you know?
Researchers at the University of California, San Diego (UCSD) have determined a key mechanism by which the body regulates iron metabolism, a discovery that may provide new approaches for the therapy of anemia. The findings, which are reported this week in the online publication of The Journal of Clinical Investigation, represent a collaborative effort between the laboratories of Randall Johnson, Ph.D., UCSD professor of biology and Victor Nizet, M.D., professor of pediatrics and pharmacy at the UCSD School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences.

Medicineworld.org: Improving Treatment Of Anemia

Acute bacterial meningitis| Alzheimer's disease| Carpal tunnel syndrome| Cerebral aneurysms| Cerebral palsy| Chronic fatigue syndrome| Cluster headache| Dementia| Epilepsy seizure disorders| Febrile seizures| Guillain barre syndrome| Head injury| Hydrocephalus| Neurology| Insomnia| Low backache| Mental retardation| Migraine headaches| Multiple sclerosis| Myasthenia gravis| Neurological manifestations of aids| Parkinsonism parkinson's disease| Personality disorders| Sleep disorders insomnia| Syncope| Trigeminal neuralgia| Vertigo|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.